SEC Comment Letter 0000000000-24-007677 to Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc.
Date: July 8, 2024 · CIK: 0001853816 · Accession: 0000000000-24-007677
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280682
Letter
July 8, 2024 Gerald T. Proehl Chief Executive Officer Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd., #322 San Diego, CA 92130 Re:Dermata Therapeutics, Inc. Registration Statement on Form S-3 Filed July 3, 2024 File No. 333-280682 Dear Gerald T. Proehl: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Steven M. Skolnick
Show Raw Text
July 8, 2024
Gerald T. Proehl
Chief Executive Officer
Dermata Therapeutics, Inc.
3525 Del Mar Heights Rd., #322
San Diego, CA 92130
Re:Dermata Therapeutics, Inc.
Registration Statement on Form S-3
Filed July 3, 2024
File No. 333-280682
Dear Gerald T. Proehl:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Steven M. Skolnick